---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-013743"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2022-03-21T23:59:59+00:00"
generated_at: "2026-06-26T21:27:48.364006+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics promotes Mahal to COO, Heller to exit, new CMO role created

## Summary
- Jeet Mahal promoted to COO (retains CFO); salary raised to $445,000, bonus target 45%.
- Kevin Heller's employment ends May 17, 2022; consulting through March 2023 at ~$37,939/month plus COBRA.
- Wendy Pang promoted to SVP of Research and Translational Medicine, effective March 21, 2022.
- New Chief Medical Officer position created; active search underway. Judith Shizuru leads clinical interim.
- All changes effective March 21, 2022, except Heller's separation date May 17, 2022.

## SEC filing metadata
- accession: 0001213900-22-013743
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2022-03-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390022013743/0001213900-22-013743-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390022013743/ea157147-8k_jasperthera.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-013743
- JSON: https://secwatch.observer/filing/0001213900-22-013743.json
- Plain text: https://secwatch.observer/filing/0001213900-22-013743.txt

## Key facts
- Executive change
  Kevin N. Heller was terminated as Executive Vice President, Research and Development at Jasper Therapeutics, Inc..
  - Action: terminated
  - Role: Executive Vice President, Research and Development
  source text: Dr. Heller’s employment with the Company will terminate, effective May 17, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390022013743/0001213900-22-013743-index.htm
- Executive change
  Jeet Mahal changed role as Chief Operating Officer and Chief Financial Officer at Jasper Therapeutics, Inc..
  - Action: promoted
  - Role: Chief Operating Officer and Chief Financial Officer
  source text: On March 18, 2022, the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) approved the promotion of Jeet Mahal, age 50, the Company’s Chief Financial Officer and Chief Business Officer, to Chief Operating Officer and Chief Financial Officer, effective March 21, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390022013743/0001213900-22-013743-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.